Author:
Sava Gianni,Bergamo Alberta
Reference56 articles.
1. Hartinger CG, Zorbas-Seifried S, Jakupec MA, et al. From bench to bedside — preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). J Inorg Biochem 2006;100:891–904.
2. Alessio E, Mestroni G, Bergamo A, et al. Ruthenium antimetastatic agents. Curr Topics Med Chem 2004;4:1525–35.
3. Kapitza S, Pongratz M, Jakupec MA, et al. Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells. J Cancer Res Clin Oncol 2005;131:101–10.
4. Kapitza S, Jakupec MA, Uhl M, et al. The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. Cancer Lett 2005;226:115–21.
5. Sava G, Zorzet S, Turrin C, et al. Dual action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen. Clin Cancer Res 2003;9:1898–905.
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献